The increasing prevalence of respiratory diseases is a significant driver for the global pulmonary function testing market. Conditions such as Chronic Obstructive Pulmonary Disease (COPD) and asthma are becoming more common due to factors like aging populations, environmental pollutants, and lifestyle changes. As these diseases grow in prevalence, there is a heightened demand for accurate and reliable diagnostic tools to manage and monitor these conditions. Pulmonary function tests are crucial for diagnosing respiratory diseases, assessing their severity, and tracking disease progression. This increased need for regular and precise testing drives the market, as healthcare providers and patients seek advanced PFT technologies to improve respiratory health outcomes and provide effective management strategies.
Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/global-pulmonary-function-testing-market
Data Bridge Market Research analyzes that the Global Pulmonary Function Testing Market is expected to reach USD 5.87 billion by 2031 from USD 3.66 billion in 2023, growing at a CAGR of 6.1% in the forecast period of 2024 to 2031.
Key Findings of the Study
Early Detection of Diseases
The increasing respiratory disorders of early detection is a key driver for the global pulmonary function testing market. The surge in respiratory disorders such as asthma, Chronic Obstructive Pulmonary Disease (COPD), and cystic fibrosis fuels the demand for pulmonary function testing. The pulmonary function tests play a crucial role in enabling early detection and efficient management of respiratory conditions, thereby improving patient outcomes and quality of life through timely intervention and treatment.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Type (Hardware, Software, and Services), Patient Type (Adult, Geriatric, and Pediatric), Application (Obstructive Lung Disease and Restrictive Lung Disease), End User (Hospital, Specialty Clinics, Diagnostics Laboratories, Home Care Settings, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Sweden, Denmark, Norway, Finland, Poland, rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Taiwan, New Zealand, Vietnam, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Qatar, Kuwait, Oman, Bahrain, Egypt, Israel and rest of Middle East and Africa
|
|
Market Players Covered
|
VYAIRE MEDICAL, INC. (U.S.), CAIRE Inc. (U.S.), Teleflex Incorporated (U.S.), PULMONE ADVANCED MEDICAL DEVICE (U.S.), COSMED srl (Italy), JK Medical System Pvt. Ltd. (India), Data Science International (U.S.), Schiller AG (Switzerland), Chest M.I. Inc. (Japan), Clarity Medical (India), CONTEC MEDICAL SYSTEMS CO., LTD (China), ECO MEDICS (Switzerland), FUKUDA SANGYO CO., LTD. (Japan), Ganshorn Medizin Electronic Gmbh (Germany), Ingmar Medical (U.S.), KoKo PFT (U.S.), MEC (Belgium), medical equipment europe Gmbh (Germany), MEDLINE (U.S.), Morgan Scientific (U.S.), Ndd Medical Technologies (U.S.), Recorders & Medicare Systems (India), Scireq (Taiwan), SIBEL, S.A.U (Spain), VITALOGRAPH (U.S.), GERATHERM MEDICAL AG (Germany), and Inofab Health (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis
Global pulmonary function testing market is segmented into four notable segments based on type, patient type, application, and end user.
- Based on type, the global pulmonary function testing market is segmented into hardware, software and services
In 2024, the hardware segment is expected to dominate the global pulmonary function testing market
In 2024, the hardware segment is expected to dominate the market with a market share of 75.58% as it constitutes of capital-intensive equipment, and the cost of hardware is a significant factor in the market. Manufacturers of these focus on developing high-quality, durable equipment to ensure accuracy and reliability, which increases their cost.
- Based on patient type, the global pulmonary function testing market is segmented into adult, geriatric and paediatric
In 2024, the adult segment is expected to dominate the global pulmonary function testing market
In 2024, the adult segment is expected to dominate the market with a market share of 59.64% as respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and lung cancer, are more prevalent in adults than in children. This increased prevalence drives demand for PFT testing in adults.
- Based on application, the global pulmonary function testing market is segmented into obstructive lung disease and restrictive lung disease. In 2024, the obstructive lung disease segment is expected to dominate the market with a market share of 97.22%
- Based on end user, the global pulmonary function testing market is segmented into hospital, specialty clinics, diagnostics laboratories, home care settings and others. In 2024, the hospital segment is expected to dominate the market with a market share of 54.56%
Major Players
Data Bridge Market Research recognizes the following companies as the major global pulmonary function testing market players in the market that include VYAIRE MEDICAL, INC. (U.S.), CAIRE Inc. (U.S.), Teleflex Incorporated (U.S.), COSMED srl (Italy), and Schiller AG (Switzerland) among others.
Market Developments
- In May 2023, Geratherm Medical AG, was honored as a "hidden champion" by the State Development Corporation of Thuringia (LEG). The recognition highlights the company's significant role in medical technology and its global market presence. Board member Christian Frick expressed gratitude for the accolade, noting the company's innovation in medical diagnostics, lung function measurement, stroke prevention, and incubator systems, which positions it well for future growth
- In January 2022, “Geratherm Medical AG discontinued its medical heating blanket” for clinical surgery, including related R&D, due to unfeasible costs for MDR certification. The decision, effective from December 31, 2021, results in a special depreciation of approximately USD 983,223 but will save around USD 436,988 annually in R&D and certification costs. The company expects no significant sales decline from this move and believes it strengthens their future position
- In April 2023, Ingmar Medical introduced RespiSim Software Version 4.3 a key advancement, including improved scenario import/export, reduced simulation lag, and enhanced platform stability. These updates significantly elevate usability and performance, making it a vital tool for respiratory therapy education and training
Regional Analysis
Geographically, the countries covered in the global Pulmonary Function Testing market report are the U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Sweden, Denmark, Norway, Finland, Poland, rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Taiwan, New Zealand, Vietnam, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Qatar, Kuwait, Oman, Bahrain, Egypt, Israel and rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the dominant region in the global pulmonary function testing market during the forecast period of 2024 to 2031
North America is expected to dominate the market as North America has a well-established healthcare infrastructure, with a high number of hospitals, clinics, and research institutions. This infrastructure provides a strong foundation for PFT testing and drives demand for PFT devices.
Asia-Pacific is the fastest growing region in the global pulmonary function testing market during the forecast period of 2024 to 2031
Asia-Pacific is the fastest growing region due to a combination of factors, including a large and increasing population, a growing prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and lung cancer, as well as an increasing awareness of the importance of early detection and diagnosis.
For more detailed information about the global pulmonary function testing market report, click here – https://www.databridgemarketresearch.com/fr/reports/global-pulmonary-function-testing-market
